Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.12408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Department of Endocrinology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Background: Fulminant type 1 diabetes mellitus (FT1DM) is a severe subtype of type 1 diabetes characterized by rapid onset, metabolic disturbances, and irreversible insulin secretion failure. Recent studies have suggested associations between FT1DM and certain medications, warranting further investigation.
Objectives: This study aims to identify drugs associated with an increased risk of FT1DM using the FDA Adverse Event Reporting System (FAERS) database, evaluate reporting patterns, and provide actionable insights to reduce FT1DM occurrence and improve medication safety.
Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report.
Am J Case Rep
January 2025
Medical School, University of Western Australia, Fremantle, Western Australia, Australia.
BACKGROUND Although hypomagnesemia is common in type 2 diabetes, clinical presentations with severe hypomagnesemia are rare. A number of oral blood glucose-lowering medications can reduce serum magnesium concentrations, and several severe cases have been reported in the presence of marked glucagon-like peptide-1 receptor agonist (GLP-1RA)-associated gastrointestinal adverse effects. In the present case, an acute presentation with severe hypomagnesemia was likely due to polypharmacy including semaglutide, albeit with a delayed relationship to discontinuation of this GLP-1RA, due to nausea and vomiting.
View Article and Find Full Text PDFEfficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial.
Adv Ther
December 2024
USV Pvt Ltd, Mumbai, Arvind Vithal Gandhi Chowk, BSD Marg, Station Road, Govandi East, Mumbai, 400 088, India.
Introduction: A slower adoption rate of fixed dose combinations (FDC) in diabetes management is partly due to insufficient data. This study evaluates the safety and efficacy of an FDC of dapagliflozin + sitagliptin + metformin hydrochloride extended release (XR), compared to a dual FDC of sitagliptin + metformin hydrochloride XR among patients with type 2 diabetes mellitus (T2DM) with poor glycemic control when treated with metformin monotherapy.
Methods: A total of 274 patients with T2DM were randomized (1:1) to either arm X, receiving FDC of dapagliflozin (10 mg) + sitagliptin (100 mg) + metformin hydrochloride XR (1000 mg) (Dapa + Sita + Met) tablets, or arm Y, receiving sitagliptin phosphate (100 mg) + metformin hydrochloride XR (1000 mg) (Sita + Met) tablets, and treated for 16 weeks.
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
PLoS One
November 2024
Department of Biostatistics and Bioinformatics, Milken Institute of Public Health, The Biostatistics Center, The George Washington University, Rockville, MD, United States of America.
Article Synopsis
- The study aimed to compare the risk of hypoglycemia among type 2 diabetes patients on metformin and adding one of four common therapies: glargine, glimepiride, liraglutide, or sitagliptin.
- The trial included 5,047 participants, assessing severe hypoglycemia events and symptoms over an average of 5 years, with a per-protocol analysis of 4,830 who completed follow-ups.
- Results showed that glimepiride had the highest incidence of severe hypoglycemia (1.3%), while liraglutide and sitagliptin had the lowest risks, indicating varying hypoglycemia likelihood based on the second medication added
A Comprehensive Narrative Review of Drug Interactions Between Traveler's Diarrhea Medications and Chronic Therapies: Implications for Clinical Practice.
Cureus
September 2024
Clinical Trial and Research Unit, Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, Chennai, IND.
Diarrhea is a common illness for travelers. Traveler's diarrhea is typically defined as experiencing at least three unformed stools per day during a stay abroad or within 10 days of returning from the destination. In this review, we consulted five databases, namely, Medicine Complete, Medscape, Drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!